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This randomised trial compared platinum-based to anthracycline-based chemotherapy in patients with small-cell lung cancer (limited
or extensive stage) and p2 adverse prognostic factors. Patients were randomised to receive six cycles of either ACE (doxorubicin
50mg/m
2 i.v., cyclophosphamide 1g/m
2 i.v. and etoposide 120mg/m
2 i.v. on day 1, then etoposide 240mg/m
2 orally for 2 days) or PE
(cisplatin 80mg/m
2 and etoposide 120mg/m
2 i.v. on day 1, then etoposide 240mg/m
2 orally for 2 days) given for every 3 weeks. For
patients where cisplatin was not suitable, carboplatin (AUC6) was substituted. A total of 280 patients were included (139 ACE,
141 PE). The response rates were 72% for ACE and 77% for PE. One-year survival rates were 34 and 38% (P¼0.497), respectively
and 2-year survival was the same (12%) for both arms. For LD patients, the median survival was 10.9 months for ACE and 12.6
months for PE (P¼0.51); for ED patients median survival was 8.3 months and 7.5 months, respectively. More grades 3 and
4 neutropenia (90 vs 57%, Po0.005) and grades 3 and 4 infections (73 vs 29%, Po0.005) occurred with ACE, resulting in more days
of hospitalisation and greater i.v. antibiotic use. ACE was associated with a higher risk of neutropenic sepsis than PE and with a trend
towards worse outcome in patients with LD, and should not be studied further in this group of patients.
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The last decades have seen considerable efforts to improve the
outcome for patients with small-cell lung cancer (SCLC) but
progress has been slow (Govindan et al, 2006). Small-cell lung
cancer is highly sensitive to chemotherapy and combination
regimens have been the cornerstone of treatment since the 1970s.
Characterisation of SCLC into limited (LD) and extensive disease
(ED) as proposed originally by the Veterans Administrator Lung
Cancer Group and revised by the International Association for the
Study of Lung Cancer (IASCL) has been the basis of treatment
choice for a number of years (Mountain, 1986; Zelen, 1973). A
number of other independent prognostic factors including
performance status (PS) and biochemical parameters (eg serum
sodium, alkaline phosphatase and serum lactate dehydrogenase)
have been identified and prognostic scores using these variables
can reliably identify patients with good, intermediate or poor
outcome (Buccheri and Ferrigno, 2004; Cerny et al, 1987; Sagman
et al, 1991; Thatcher et al, 1995).
When the current trial was designed in 1999, trials comparing
platinum-based with anthracycline-based chemotherapy in
SCLC were ongoing and the importance of concurrent chemo-
radiotherapy was just beginning to be understood. The
ACE combination was still widely used in Europe (Thatcher et al,
2000; Sambrook and Girling, 2001) and was a reference regimen
for the European Organisation for Research and Treatment of
Cancer (EORTC) Lung Group (Ardizzoni et al, 2002; Giaccone
et al,1 9 9 3 ;P o s t m u set al, 1996). Median survivals of 9–11 months
with 1-year survival of 30–40% were reported in trials of both LD
and ED patients with good PS (Giaccone et al, 1993; Thatcher et al,
2000; Urban et al, 1999). However, treatment with ACE was
associated with significant neutropenia that contributed to infec-
tion-related morbidity and mortality (Bunn et al, 1986; Postmus
et al,1 9 9 6 ;T h a t c h e ret al, 2000). Cisplatin and etoposide (PE) were
widely used in North America, with similar survival rates to those
reported for cyclophosphamide, doxorubicin, vincristine (CAV)
(Fukuoka et al, 1991; Roth et al, 1992). Carboplatin was shown to be
active in the treatment of SCLC, and one randomised study
comparing carboplatin and etoposide with PE showed no difference
in survival, though the study was not powered for equivalence
(Kosmidis et al, 1994).
When this clinical trial was designed in 1999, there were
no published data from studies comparing ACE with a plati-
num/etoposide combination in patients with better-prognosis
disease. Received 23 August 2007; revised 4 June 2008; accepted 5 June 2008
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sMETHODS
The study design was a randomised phase III comparison of ACE
with platinum/etoposide chemotherapy as first-line therapy in
patients with better-prognosis SCLC.
Eligibility criteria
Previously untreated patients with histologically or cytologically
proven SCLC and a maximum of two adverse prognostic factors
(extensive stage disease, PS X2, raised LDH, serum sodium
o130mmoll
 1, Alk Phos 41.25 ULN) were eligible. Other eligi-
bility criteria included age X18 years, normal blood count, serum
bilirubin o35mmoll
 1 and creatinine clearance 450mlmin
 1.I n
patients with impaired renal function, that is, creatinine clearance
430mlmin
 1 but o50mlmin
 1, and/or patients with significant
cardiovascular disease, carboplatin could be substituted for
cisplatin in the first or subsequent cycles.
A CT brain scan was not routinely performed, but patients with
known brain metastases were not eligible.
The study had ethical and local approval and was covered by
a DDX, later updated to a CTA after the introduction of
EU Regulations. Patients gave their written informed consent.
The Trial Management Committee consisted of the PI, the
Co-Investigator, the lead research sister and the data manager.
Adverse events were discussed by the TMC and those defined
as serious and unexpected events were reported to the ethics
committee.
After the publication in 2004 of two studies suggesting a survival
benefit for platinum/etoposide in LD patients (Sundstrom et al,
2002; Thatcher et al, 2005), accrual of the final 12 patients required
was limited to patients with extensive stage disease.
Treatment and monitoring
Patients were randomised to receive six cycles of ACE (doxo-
rubicin 50mg/m
2 i.v., cyclophosphamide 1g/m
2 i.v. and etoposide
120mg/m
2 i.v. on day 1, followed by etoposide 240mg/m
2
orally for 2 days) for 3 weeks or six cycles of PE (cisplatin
80mg/m
2 and etoposide 120mg/m
2 i.v. on day 1, followed by
etoposide 240mg/m
2 orally for 2 days every 3 weeks). For patients
where cisplatin was not suitable, carboplatin was substituted
at an AUC of 6, calculated according to the Calvert formula (ie,
carboplatin dose¼target AUC of 6 (glomerular filtration
rateþ25mg), where glomerular filtration rate was based on EDTA
or measured creatinine clearance).
Chemotherapy was given if the total WBC was X3000m/l,
neutrophils X1500m/l, platelets X100000m/l and creatinine
clearance X30mlmin
 1, and there was no evidence of severe
toxicity. If these conditions were not fulfilled, treatment was
delayed and the blood count was repeated at intervals of not more
than 1 week; treatment was given at full dose as soon as the above
conditions were met. Dose reduction was not recommended. The
use of GCSF as secondary prophylaxis was at the discretion of the
investigator.
Thoracic radiotherapy was given to patients with limited stage
disease achieving a complete or partial response to chemotherapy,
beginning 3 weeks after the last cycle of chemotherapy (30Gy in 10
daily fractions). Patients with ED SCLC received thoracic
irradiation only if they had thoracic symptoms amenable to
palliation with radiotherapy after completion of chemotherapy.
Prophylactic cranial irradiation was considered for all LD patients
achieving a complete response; suitable patients received 25Gy in
10 daily fractions after completion of chemotherapy.
Tumour stage was assessed with CT scan of thorax and
abdomen. Disease measurement was performed within 4 weeks
before the start of treatment. During chemotherapy, patients were
assessed on days 1 and 15 with physical examination, and weekly
with blood count, biochemistry and WHO Performance Status. A
chest X-ray (CXR) was carried out after every second cycle of
treatment, but assessment of response was made according to the
WHO criteria by CT scanning at the end of chemotherapy unless
progressive disease was detected in the interim by CXR. Toxicities
were graded according to the National Cancer Institute Common
Toxicity Grading Criteria version December 1994 (revised).
Statistical design
The study design was a randomised phase III comparison of ACE
with platinum/etoposide as first-line therapy for patients with
SCLC and a maximum of two adverse prognostic factors. The
primary end point was 1-year survival. Secondary end points were
2-year survival, median survival, response rate and toxicity.
Survival was calculated from the date of randomisation to the
date of death from any cause. Time to progression was taken from
the date of randomisation to the date of the progression. A 1-year
survival of 40% had been reported for ACE in a recent MRC study
(Thatcher et al, 2000). The North American experience suggested a
1-year survival rate of approximately 60% for a platinum-based
combination, possibly in a more favourable patient group (Evans
et al, 1987). Two hundred eighty patents were required to detect a
survival difference of 20% (from 40 to 60%) at 1-year, with 90%
power and a two-sided significance level of 5%. Patients were
randomized on a 1:1 basis to one of two treatment arms. The
allocation method was stochastic minimisation as implemented in
a bespoke computer application at the randomisation centre. The
only factor controlled for in the allocation was centre.
RESULTS
Patient’s characteristics
Between April 1999 and February 2005, 280 patients (ACE¼139,
PE¼141) were randomised at two centres in the UK. The two arms
were well balanced for age, stage, gender, PS and prognostic score
(Table 1). All patients were included in the survival analysis on an
intention to treat basis. Two patients were ineligible because of
incorrect histological diagnosis (non-SCLC), one for each arm. A
further seven patients were not assessable for response, three in
the ACE arm (one patient received PE while was waiting for
Table 1 Patient and tumour characteristics
ACE PE Total P-value
No. of patients 139 141 280
Male/female 67/72 75/66 142/138 0.47
Median age, years (range) 66 (38–81) 65 (39–89) 0.95
Stage
Limited 84 (60) 81 (57) 165 0.65
Metastatic 54 (39) 60 (43) 112
Limited stage, good PS,
normal LDH
21% 29%
Prognostic score (MS)
0 31 (22) 41 (29) 72
1 63 (45) 56 (40) 119
2 45 (33) 40 (28) 85
3 0 (0) 4 (3) 4 0.1
Performance status (WHO)
0 19 (14) 20 (14) 39
1 82 (59) 83 (59) 165
2 36 (26) 37 (26) 73
3 1 (1) 1 (1) 2
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sinvestigations, one died before cycle 1 and one needed radio-
therapy following first cycle) and four patients in the PE arm (one
died before cycle 1, one stopped the treatment after first cycle
because of toxicity and two lost to follow-up after first cycle)
(Figure 1).
Treatment received
A total of 584 cycles of ACE and 696 of PE were administered
(P¼0.001) (Table 2). Fifty-two (37%) of the 139 patients
randomised to ACE and 91 (65%) of patients randomised to
platinum/etoposide completed all six cycles (P¼0.01). The main
reasons for early discontinuation were disease progression (ACE
19%, PE 12%) and toxicity (ACE 30%, PE 12%). Thirty-eight per
cent of cycles of ACE were delayed or discontinued due to toxicity
compared with 30% for PE (P¼0.048). Six patients in the PE arm
received carboplatin rather than cisplatin on cycle 1, and
carboplatin was substituted for cisplatin during the treatment in
a further four patients; one patient changed from PE to single-
agent carboplatin.
In patients with limited stage disease, 58% patients in the ACE
arm and 74% of patients in the PE arm received consolidation
thoracic radiotherapy (P¼0.04) and 23% of ACE patients and 33%
of PE patients received PCI (P¼0.24). A further 20 (14%) patients
in the ACE arm and 12 (8.5%) in the PE arm received palliative
radiotherapy. At disease progression, radiotherapy was given to 31
(22%) patients in the ACE arm and to 19 (13%) patients in the PE
arm. Twenty-five (18%) and 21 (15%) of patients received second-
line chemotherapy in the ACE arm and PE arm, respectively.
Toxicity
Clinically significant toxicity was more common in patients
receiving ACE (Table 3). Grades 3 and 4 anaemia occurred in 37
(27%) patients on the ACE arm and 25 (18%) patients on the PE
arm (P¼0.038). Grades 3 and 4 neutropenia occurred in 123 (90%)
of patients receiving ACE and 78 (57%) of patients receiving PE
(Po0.005). Neutropenia was associated with a high incidence of
grades 3 and 4 infections, 73% of patients receiving ACE and 29%
receiving PE arm (Po0.005). Eighty-two percent of patients in the
ACE arm required i.v. antibiotics for one or more days during their
treatment compared with 37% of PE patients. Hospitalisation for
severe neutropenia and infections was less frequent with PE
compared with ACE. The total number of days of hospitalisation
for those treated with ACE was 1390 compared with 360 for PE
(Po0.005). The median number of days of hospitalization was 9
(0–45) for ACE and 0 (0–18) for PE. Non-haematological toxicity
was similar in both arms, but patients receiving PE experienced
more grades 2 and 3 nausea.
Response and survival
The response rate was higher for PE patients, with a higher
number of complete responders (Table 4). There was no significant
difference in overall, median, 1-year or 2-year survival between the
two treatment arms (Table 5 and Figure 2). For the LD group, the
median survival was 10.9 months for ACE and 12.6 months for PE
(P¼0.58), with an actual 1-year survival rate of 44 and 54%,
respectively (P¼0.2). For the ED group, median survival was 8.3
months for ACE and 7.5 months for PE, with an actual 1-year
survival rate of 17 and 15%, respectively. (P¼0.9).
DISCUSSION
Although PE is now considered the treatment of choice for fitter
patients with SCLC, this was not the case when the current trial
Table 2 Number of cycles treatment administered
ACE PE
N 137 (%) 140 (%) P-value
No. of cycles
0 2 (2) 1 (1)
1 18 (13) 11 (8)
2 11 (8) 7 (5)
3 14 (10) 11 (8)
4 20 (14) 8 (6)
5 22 (16) 12 (9)
6 52 (37) 91 (65) 0.001
Total 584 696
Randomisation 
n=280
ACE 
n=139 
PE
n=141
Analysed 
for
efficacy 
n=135
Analysed 
for efficacy 
n=135
Received <6 cycles, 
n=87
Received <6 cycles, 
n=50
Completed 6 cycles, 
n=52
Completed 6 cycles, 
n=91
Ineligible: 
1 NSCLC 
____________ 
Error 1 given PE 
Ineligible: 
1 NSCLC 
4 MS score 3 
(assessed)
Not assessable
1 died prior to cycle 1 
1 cycle 1  →XRT 
Not assessable
1 died prior to cycle 1 
1 stopped toxicity 
2 lost to FU 
Figure 1 ACE/PE study flow diagram (CONSORT).
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swas being designed. Several prospective studies had compared PE
with anthracycline-based therapy, but most failed to demonstrate
superiority of PE (Evans et al, 1987; Fukuoka et al, 1991; Roth et al,
1992). Subsequently, an overview of US National Cancer Institute
sponsored trials for ED patients conducted between 1972 and
1990 demonstrated that cisplatin-based regimens were associated
with an improved median survival (Chute et al, 1999) and a meta-
analysis of 19 trials published between 1981 and 1999 showed a
small survival benefit for patients receiving cisplatin-based
chemotherapy (Pujol et al, 2001). Etoposide-containing regimens,
with or without cisplatin, were also shown to be associated with a
significant survival benefit (Mascaux et al, 2000).
After this study had begun accrual, a trial from Norway
comparing PE with cyclophosphamide, epirubicin, etoposide
(CEV) reported a survival benefit for PE (Sundstrom et al, 2002).
The median survival was 7.8 months for CEV and 10.2 months for
PE, with a 2-year survival of 6 and 14%, respectively (P¼0.0004).
The advantage was confined to patients with LD, with a median
survival of 14.5 months for PE and 9.7 months for CEV (P¼0.001),
and a 2-year survival of 25 and 10% (P¼0.0001), respectively.
There was a trend in the same direction for patients with ED, but
this was not statistically significant. Although the proportions of
patients with extensive stage disease and with PS2 were similar in
both studies, the choice and doses of drugs are not directly
comparable. The comparator arm in the Norwegian study used a
lower dose of anthracycline (epirubicin 50mg/m
2 vs doxorubicin
50mg/m
2) and used vincristine rather than etoposide. The median
survival for PE was similar in both studies (10.6 vs 10.2 months).
The different survival seen for the two-comparator arms (7.8
months for CEV vs 9.6 months for ACE) may explain in part the
statistically significant survival advantage seen for PE in the
Sundstrom study. The survival for ACE in this study is marginally
Table 4 Response to treatment (N¼280)
Response to treatment ACE (%) PE (%)
Complete response 25 (18) 36 (26)
Partial response 72 (53) 70 (50)
stable disease 6 (4) 13 (9)
Progressive disease 27 (20) 17 (12)
Toxic death 2 (1) 1 (1)
Not assessable 5 (4)
a 3 (2)
b
aOne patient died before cycle 1; one had PE; one had XRT following first cycle; one
died after cycle 1 due to toxicity not assessed; one stopped after cycle 1 due to toxicity.
bOne patient stopped after cycle 1 due to toxicity not assessed; two lost to FU.
Table 5 Survival
ACE PE
All Patients
Median survival (months) 9.7 10.6
1-year survival (%) 34 38
2-year survival (%) 12 12
LD
Median survival (months) 10.9 12.6
1-year survival (%) 44 54
2-year survival (%) 19 16
ED
Median survival (months) 8.3 7.5
1-year survival (%) 17 15
2-year survival (%) 0 3
Table 3 Toxicity
ACE (N¼137), no. of patients (%) PE (N¼140), no. of patients (%)
Toxicity Grades 1 and 2 Grades 3 and 4 Grades 1 and 2 Grades 3 and 4
Haematologic adverse events
Anaemia 88 (64) 38 (28) 96 (69) 27 (19)
Neutropenia 3 (2) 125 (91) 47 (34) 82 (59)
Thrombocytopenia 36 (26) 77 (56) 39 (28) 69 (49)
Non-haematologic adverse events
Infection 13 (9) 100 (73) 24 (18) 40 (39)
Nausea 65 (47) 06 (4) 75 (55) 13 (9)
Vomiting 41 (30) 3 (2) 52 (38) 8 (6)
Constipation 37 (27) 2 (1) 55 (41) 4 (3)
Oral mucositis 63 (46) 9 (7) 50 (37) 2 (1)
Lethargy 80 (59) 13 (9) 96 (70) 14 (10)
Anorexia 68 (50) 8 (6) 76 (56) 5 (4)
Alopecia (grades 1–3) 42 (31) 52 (38) 65 (48) 72 (51)
Hoarse voice 35 (26) 2 (1) 27 (20) 6 (4)
Neuropathy 16 (12) 0 29 (21) 1 (1)
Cough 84 (61) 1 (1) 84 (62) 4 (3)
N¼137 (%) N¼136 (%) P-value
Intravenous/oral antibiotics during all cycles
No. of patients None 17 (12) 67 (49)
Oral only 3 (2) 17 (13) o0.005
Intravenous only 52 (38) 21 (16)
Intravenous+oral 60 (44) 29 (21)
NK 5 (4) 2 (1)
No. of cycles Affected/ 243/578 76/685 o0.005
possible (%) (42) (11)
No. of days Affected/ 1390/12138 360/14385 o0.005
possible (%) (11) (3)
NK¼not known.
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slower than that reported for two studies from the UK Medical
Research Council, but these studies had fewer ED patients
(Thatcher et al, 2000; Thatcher et al, 2005).
The median and 2-year survivals for PE in LD patients in our
study were lower than those reported by Sundstrom (12.6 vs 14.5
months, 21 vs 25%, respectively). This may in part reflect lower use
of radiotherapy, which has an established role in consolidating the
response of the primary tumour to chemotherapy and in reducing
the risk of brain metastases as a site of recurrence. (Pignon et al,
1992; Warde and Payne, 1992). Cisplatin plays a central role in
concurrent treatment, because of its radiosensitising effect, and
there is increasing evidence of a survival benefit for patients
receiving early, concurrent, cisplatin-based chemoradiotherapy
with 5-year survival ranging between 20 and 25% (Fried et al, 2004;
Pijls-Johannesma et al, 2005). In this study, thoracic radiotherapy
was given after the completion of chemotherapy. The rate or TRT
was lower for patients receiving ACE (58%) than those receiving
PE (74%). The reason for this is unclear, but is likely to reflect the
worse toxicity seen with ACE, and is similar to the 51–54%
reported in comparable studies (Thatcher et al, 2000; Ardizzoni
et al, 2002). Higher TRT rates have also been reported for other
platinum combinations (Lorigan et al, 2005; Thatcher et al, 2005).
The TRT rate in the Sundstrom study was higher in both arms
(83 and 88%). Prophylactic cranial irradiation has been shown to
be associated with a survival advantage in LD and ED patients
responding to chemotherapy (Auperin et al, 1999) (Slotman et al,
2007). In this study, 33% of LD patients receiving PE and 23% of
those receiving ACE went on to have PCI. The use of PCI was
comparable with the Sundstrom study, but lower than that
reported in studies using VICE (35–53%) (Lorigan et al, 2005;
Thatcher et al, 2005).
We observed that haematological toxicity and the risk of infection
were significantly higher for ACE than for PE. This difference was
clinically relevant, with a higher rate of grades 3 and 4 infection,
higher number of days in hospital and higher rate of treatment
discontinuation for ACE. The incidence of grades 3 and 4 infection
in this study was 73% for ACE, and 29% for PE. Intravenous
antibiotics were used in 82% of patients receiving ACE and 37% of
patients receiving PE. The infection rates seen in both arms of this
study were substantially higher than the 14–15% reported for ACE
and 16% for VICE – toxicity data were not reported for the
Sundstrom study. (Thatcher et al,2 0 0 5 ;T h a t c h e ret al,2 0 0 0 )
However, the toxic death rate (1%) is lower than the 4–10%
reported in other comparable studies (Thatcher et al, 2000; Pujol
et al, 2001; Ardizzoni et al, 2002). The likely explanation for the
high-recorded infection rate but low toxic death rate in both arms
was that patients were seen weekly and clinical teams had a low
threshold for responding to neutropenia. Other factors (low use of
GCSF, lack of use of prophylactic antibiotics, use of oral etoposide,
higher proportion of ED patients) may also have contributed to the
proportionally higher infection rate seen in both arms.
The study was initially designed to allow inclusion of patients not
fit for cisplatin chemotherapy, allowing these to be treated with
carboplatin. We were surprised by the low number of patients (six)
who commenced treatment with carboplatin. A further four patients
changed to carboplatin during treatment. We have included these
patients with cisplatin for both efficacy and toxicity analysis.
Further advances in the treatment of patients with SCLC are
most likely to come with optimum use of concurrent chemother-
apy and radiotherapy, and the identification of new drugs and
targets. Until then, the combination of cisplatin and etoposide is
standard therapy for patients with SCLC and good PS, and further
studies of traditional anthracycline-based regimens are not
warranted.
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